BANGALORE Satyam Computer Services Ltd(SATY.NS) handily beat expectations with a 20.6 percent rise in third-quarter profit before a one-off loss, joining larger rivals like Infosys(INFY.NS) in signalling a pickup in outsourcing spend.
The company, now called Mahindra Satyam, is in the last lap of a merger with parent Tech Mahindra Ltd (TEML.NS). Profits for the December quarter rose to 3.74 billion rupees from 3.10 billion rupees a year earlier, the company said on Thursday. That compares with analysts' estimate of 2.81 billion rupees, according to Thomson Reuters I/B/E/S.
Profit after the one-off loss of 2.94 bln rupees was 800 million rupees, Satyam said.
Satyam paid $68 million to Aberdeen Global and 22 funds to fully settle claims related to an accounting fraud that led to the sale of the Hyderabad-based company to Tech Mahindra, the company had said on December 13.
Satyam was sold in a government-backed auction in 2009 after its founder and former chairman admitted to one of the country's biggest accounting frauds.
A surprise increase by second-ranked Infosys (INFY.NS) in revenue forecast for the current fiscal year and strong earnings at top-ranked Tata Consultancy Services (TCS.NS) earlier this month prompted speculation of a pickup in outsourcing spending in the sector's biggest market, the United States.
Such a pickup would help Satyam's parent Tech Mahindra accelerate its growth towards its aim of doubling consolidated revenue to about $5 billion in 2015. The combined company would be India's fifth-largest software services provider, with customers such as BT Group PLC and SAAB AB.
Tech Mahindra owns close to 43 percent of Satyam. It is offering one share in itself for every 8.5 shares of Satyam to absorb the company. The merger may be complete by March, the company had said.
(Reporting by Harichandan Arakali; Editing by Anand Basu)
Trending On Reuters
The U.S. Department of Justice (DoJ) has subpoenaed India's largest drugmaker Sun Pharmaceutical Industries Ltd seeking information about the pricing and marketing of the generic drugs it sells in the United States, the company said on Saturday. Full Article